210 related articles for article (PubMed ID: 8353089)
1. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
8. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Campora E; Oliva C; Mammoliti S; Cetto GL; Fosser V; Marangolo M; Rosso R
Breast Cancer Res Treat; 1991 Oct; 19(2):129-32. PubMed ID: 1836746
[TBL] [Abstract][Full Text] [Related]
9. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.
Stewart A; McQuade B; Cronje JD; Goedhals L; Gudgeon A; Corette L; Froger X; Tubiana-Hulin M; Laplaige P; Roberts JT
Oncology; 1995; 52(3):202-10. PubMed ID: 7715904
[TBL] [Abstract][Full Text] [Related]
11. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
12. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B
Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Thamlikitkul L; Srimuninnimit V; Akewanlop C; Ithimakin S; Techawathanawanna S; Korphaisarn K; Chantharasamee J; Danchaivijitr P; Soparattanapaisarn N
Support Care Cancer; 2017 Feb; 25(2):459-464. PubMed ID: 27714530
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
16. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Ishida T; Kusaba T; Hayakawa H
Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
[TBL] [Abstract][Full Text] [Related]
17. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Beck TM; Ciociola AA; Jones SE; Harvey WH; Tchekmedyian NS; Chang A; Galvin D; Hart NE
Ann Intern Med; 1993 Mar; 118(6):407-13. PubMed ID: 8439113
[TBL] [Abstract][Full Text] [Related]
19. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Beck TM; York M; Chang A; Navari R; Harvey WH; Meshad M; Griffin D; Wentz A
Cancer Invest; 1997; 15(4):297-303. PubMed ID: 9246149
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]